A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This single-center, randomized, double-blind, two-period crossover study will evaluate the
safety, tolerability, pharmacokinetics and pharmacodynamic effects of the combination of
multiple doses of RO5285119 with a single dose of risperidone in healthy volunteers. Subjects
will be randomized to one of 4 treatment sequences of two periods to receive multiple doses
of RO5285119 plus a single dose of risperidone or risperidone placebo or multiple doses of
RO5285119 placebo plus a single dose of risperidone or risperidone placebo, with a washout
period of approximately 3 weeks between treatment periods. Anticipated time on study is up to
12 weeks (from screening through study completion).